Development of a High-Throughput Size-Exclusion Chromatography–Mass Spectrometry Workflow for Real-Time Monitoring of Bioconjugation of Cysteine-Based Antibody–Drug Conjugates
Bioconjugate Chemistry · 15.07.2026 · 37 (7) · 1421-1429
DOI: 10.1021/acs.bioconjchem.6c00182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 18.06.2026. Verfasst von Zhengqi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States. Hauptthemen laut MEDLINE: Immunoconjugates, Cysteine, Chromatography, Gel, Mass Spectrometry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
The manufacturing of cysteine-based antibody-drug conjugates (ADCs) requires precise control of the drug-to-antibody ratio (DAR), a critical quality attribute influencing product safety and efficacy. Conventional analytical techniques used for DAR determination, such as hydrophobic interaction chromatography (HIC) and reversed-phase high-performance liquid chromatography (RP-HPLC), are low-throughput and unsuitable for real-time process monitoring, limiting process development efficiency. To address this challenge, we developed a high-throughput size-exclusion chromatography-mass spectrometry (SEC-MS) workflow with and without postcolumn denaturation (PCD) functionality, enabling real-time monitoring of both reduction and conjugation kinetics during cysteine-based ADC manufacturing. Using a short SEC column coupled to a mass spectrometer, analysis time can be performed under 2 min per sample. This workflow was applied to rapidly optimize critical process parameters, including reductant concentration and pH during reduction, and drug-linker ratio during conjugation. The approach provided deeper mechanistic insights into reaction kinetics and supports process analytical technology (PAT)-enabled strategies for advanced process control. Overall, this high-throughput SEC-MS workflow accelerates ADC development while improving manufacturing robustness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Analytical Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
- Department of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana 47907, United States.
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
ORCID-Profile: Pei-Ru Jin, Wei Lin, Hong Ren
Zitieren
APA
Zhang, Z., Jin, P. R., Lin, W., Liang, T., Deyanova, E., Gunawan, R., & Ren, H. (2026). Development of a High-Throughput Size-Exclusion Chromatography–Mass Spectrometry Workflow for Real-Time Monitoring of Bioconjugation of Cysteine-Based Antibody–Drug Conjugates. Bioconjugate Chemistry, 37(7), 1421-1429. https://doi.org/10.1021/acs.bioconjchem.6c00182
Vancouver
Zhang Z, Jin PR, Lin W, Liang T, Deyanova E, Gunawan R, et al. Development of a High-Throughput Size-Exclusion Chromatography–Mass Spectrometry Workflow for Real-Time Monitoring of Bioconjugation of Cysteine-Based Antibody–Drug Conjugates. Bioconjugate Chemistry. 2026;37(7):1421-1429. doi:10.1021/acs.bioconjchem.6c00182
BibTeX
@article{Zhang2026,
author = {Zhang, Zhengqi and Jin, Pei-Ru and Lin, Wei and Liang, Tao and Deyanova, Ekaterina and Gunawan, Rico and Ren, Hong},
title = {Development of a High-Throughput Size-Exclusion Chromatography–Mass Spectrometry Workflow for Real-Time Monitoring of Bioconjugation of Cysteine-Based Antibody–Drug Conjugates},
journal = {Bioconjugate Chemistry},
year = {2026},
volume = {37},
number = {7},
pages = {1421--1429},
doi = {10.1021/acs.bioconjchem.6c00182}
}
EUVIMED